How to Get Oral Micronized Progesterone in North Carolina

At a glance
- Drug / progesterone (Prometrium), 100 mg and 200 mg oral capsules
- NC telehealth prescribing / fully legal for hormone therapy
- Who can prescribe / MDs, DOs, NPs, PAs with NC prescriptive authority
- Typical dose / 200 mg nightly for 12 days per cycle (cyclic) or 100 to 200 mg nightly (continuous)
- 503A compounding / available in NC for custom dosing
- NC Medicaid / does not cover progesterone for endometrial protection on HRT (covers type 2 diabetes indication only)
- Private insurance / most commercial plans cover generic progesterone with copay
- Labs before starting / serum progesterone, estradiol, CBC, metabolic panel
- Timeline / prescription to delivery typically 3 to 7 business days via telehealth
- FDA status / approved 1998 for secondary amenorrhea and endometrial protection in postmenopausal women on estrogen
What Is Oral Micronized Progesterone and Why Is It Prescribed?
Oral micronized progesterone is a bioidentical form of the hormone progesterone, suspended in peanut oil and delivered as a soft gelatin capsule. The FDA approved Prometrium in 1998 for two indications: treatment of secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens 1.
The clinical case for micronized progesterone over synthetic progestins rests on the PEPI trial. That 1995 JAMA study (N=875) randomized postmenopausal women to five HRT regimens and found that micronized progesterone combined with conjugated equine estrogens raised HDL cholesterol more favorably than medroxyprogesterone acetate (MPA), while still protecting the endometrium from hyperplasia 2. The PEPI investigators wrote: "Micronized progesterone did not diminish the beneficial effects of estrogen on HDL cholesterol, as did medroxyprogesterone acetate." This finding changed prescribing patterns nationwide, and the 2022 Endocrine Society clinical practice guidelines now list micronized progesterone as a first-line option for endometrial protection in menopausal hormone therapy 3.
For North Carolina patients, the practical question is access. The drug requires a prescription, and the route to that prescription depends on provider type, insurance coverage, and pharmacy availability.
Telehealth Prescribing for Progesterone in North Carolina
North Carolina law permits licensed providers to prescribe progesterone via telehealth. That is the short answer.
NC General Statute §90-21.1A defines telehealth broadly and allows prescribing after an appropriate provider-patient relationship has been established through synchronous audio-video communication 4. The state does not require an initial in-person visit before prescribing hormone therapy, which means a patient in Raleigh, Charlotte, or Asheville can complete the entire process from home.
A typical telehealth workflow looks like this: the patient completes an intake form documenting symptoms, medical history, and current medications. The provider reviews the intake, orders baseline labs (discussed below), and schedules a video consultation. If clinically appropriate, the provider writes a prescription for oral micronized progesterone and sends it electronically to the patient's preferred pharmacy.
Turnaround varies by platform. Some telehealth providers deliver a prescription within 24 to 48 hours of the video visit. Others batch lab reviews weekly. Ask about timeline before committing. Patients in rural NC counties, where OB-GYN wait times can stretch 6 to 8 weeks according to 2023 AAMC workforce data 5, may find telehealth particularly practical.
Who Can Prescribe in NC: MD, NP, and PA Scope
Multiple provider types hold prescriptive authority for progesterone in North Carolina. MDs and DOs can prescribe without restriction. Nurse practitioners in NC gained full practice authority under Session Law 2024-30 (effective July 2025), which removed the requirement for a collaborative practice agreement after 6,000 hours of supervised practice. NPs who have met this threshold can independently prescribe progesterone and other Schedule-unscheduled medications.
Physician assistants retain supervisory requirements. A PA in NC must have a supervising physician who has approved prescribing of the relevant drug category. Progesterone is not a controlled substance, so it does not trigger DEA-specific restrictions for PAs.
For patients: the provider's license type matters less than their clinical familiarity with hormone therapy. A family medicine NP who manages 200 menopausal patients will likely write a more appropriate regimen than a specialist who rarely prescribes HRT. Ask the provider how many HRT patients they manage before scheduling.
Baseline Labs Required Before Starting Progesterone in NC
No NC-specific statute mandates particular labs before a progesterone prescription, but standard-of-care guidelines apply statewide.
The North American Menopause Society (NAMS) 2022 position statement recommends baseline assessment including serum estradiol, FSH (if menopausal status is uncertain), a complete metabolic panel, CBC, lipid panel, and a review of mammography status 6. Most prescribers also order a serum progesterone level to establish a pre-treatment baseline, though this is optional for clearly postmenopausal women.
Telehealth platforms typically direct patients to a local lab draw facility. Quest Diagnostics and Labcorp both operate extensive networks across NC, with locations in all 100 counties or within a 30-minute drive. Some platforms ship at-home finger-prick kits, but venous draws remain the gold standard for hormone panels because of superior analytical precision.
Lab results are usually available within 2 to 3 business days. The prescriber reviews them before the video visit or, in some models, during the consultation itself.
North Carolina Pharmacy Options: Retail and 503A Compounding
Generic micronized progesterone capsules (100 mg and 200 mg) are stocked at most retail pharmacies in NC, including CVS, Walgreens, and independent pharmacies. GoodRx data from May 2026 shows a cash price range of $15, $45 for a 30-day supply of generic progesterone 200 mg, depending on the pharmacy 7.
For patients who need custom dosing (e.g., 150 mg capsules, sublingual troches, or topical creams), NC-licensed 503A compounding pharmacies can fill a patient-specific prescription. Under the Drug Quality and Security Act (2013), 503A pharmacies compound medications pursuant to individual prescriptions and are regulated by the NC Board of Pharmacy 8. Several NC-based compounding pharmacies also hold licenses to ship within the state.
Patients should confirm that the compounding pharmacy uses USP-grade micronized progesterone powder and follows USP <795> standards for nonsterile compounding. This is not a theoretical concern. A 2020 JAMA Internal Medicine study found significant dose variability in compounded hormone preparations, with 34% of tested samples falling outside the acceptable potency range of 90 to 110% 9.
Insurance Coverage and Prior Authorization in NC
Commercial insurance coverage for generic oral micronized progesterone is common. Most BlueCross BlueShield of NC, Aetna, Cigna, and UnitedHealthcare plans cover generic progesterone on a preferred-brand or Tier 2 formulary tier. Copays typically range from $5, $25 for a 30-day supply. Brand-name Prometrium may require Tier 3 copay or prior authorization.
NC Medicaid presents a different picture. As of 2026, NC Medicaid does not cover oral micronized progesterone for endometrial protection on HRT. Coverage exists only for the type 2 diabetes indication, which is an off-label but evidence-supported use. Patients on Medicaid who need progesterone for HRT may need to pursue a formulary exception or pay out of pocket.
Prior authorization, when required, typically demands documentation of the clinical indication (e.g., endometrial protection while on estrogen therapy), confirmation that the patient has a uterus, and evidence that baseline labs have been completed. The prescribing provider submits a PA request to the insurer, which by NC Department of Insurance regulation must respond within 3 business days for non-urgent requests.
The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 states: "In women with a uterus who are prescribed systemic estrogen therapy, a progestogen should be added to reduce the risk of endometrial cancer" 10. Citing this guideline in a PA letter strengthens the clinical justification.
Dosing Protocols: Cyclic vs. Continuous
Two standard dosing schedules exist for endometrial protection, and both are available to NC patients.
Cyclic dosing calls for 200 mg nightly for 12 to 14 days of each calendar month. This approach produces a predictable withdrawal bleed, which some patients prefer because it mimics a natural cycle and provides reassurance that the endometrium is shedding. The PEPI trial used 200 mg for 12 days per month and documented adequate endometrial protection at that dose 2.
Continuous dosing uses 100 mg nightly every day without a break. This protocol is preferred by patients who want to avoid monthly bleeding. The E3N prospective cohort (N=80,377) followed French women on various HRT regimens and found no increased breast cancer risk with micronized progesterone over a median follow-up of 8.1 years, compared with a relative risk of 1.69 for synthetic progestins 11. The study provided observational support for the safety profile of micronized progesterone specifically.
Prometrium capsules contain peanut oil. Patients with peanut allergies should use a compounded formulation in an alternative carrier oil. This is clinically relevant and frequently overlooked.
Timing matters: progesterone causes drowsiness. The FDA label recommends bedtime dosing because peak serum levels occur 1 to 3 hours after ingestion and the sedative effect is clinically meaningful 1. Patients who take it in the morning risk daytime somnolence.
Transferring an Existing Progesterone Prescription to NC
Patients relocating to North Carolina from another state can transfer an active progesterone prescription. NC Board of Pharmacy regulations allow inter-state prescription transfers for non-controlled substances, which includes progesterone.
The process requires the receiving NC pharmacy to contact the originating pharmacy, verify the prescription, and document the transfer. Both pharmacies must record the transfer in their dispensing logs. This typically takes 1 to 2 business days.
One caveat: compounded prescriptions from out-of-state 503A pharmacies cannot always be transferred because the compound may not match the NC pharmacy's available formulations. In that case, the patient's new NC provider needs to write a new prescription.
Telehealth prescriptions present a separate consideration. If the patient's telehealth provider is licensed in both the originating state and NC, they can continue prescribing without interruption. If the provider lacks an NC license, the patient will need a new prescriber. Multi-state telehealth platforms that employ NC-licensed providers solve this problem automatically.
Side Effects and Monitoring After Starting Progesterone
The most common side effects of oral micronized progesterone include drowsiness (reported in 31% of patients in clinical trials), dizziness (15%), abdominal pain (10%), and headache (13%) 1. These rates come from the Prometrium prescribing information based on controlled clinical trials.
Monitoring after initiation follows NAMS recommendations: a follow-up visit (in-person or telehealth) at 3 months to assess symptom response and side effects, then every 6 to 12 months thereafter 6. Repeat hormone levels are optional and should be guided by clinical response rather than numbers alone.
Endometrial monitoring deserves attention. Any unexpected vaginal bleeding after the first 6 months of continuous combined HRT warrants transvaginal ultrasound and possible endometrial biopsy. The Endocrine Society recommends against routine endometrial surveillance in asymptomatic women on standard-dose HRT 3.
Patients on cyclic dosing should expect a withdrawal bleed within 2 to 5 days of completing the 12-day progesterone course. Absence of withdrawal bleeding for two consecutive cycles should prompt clinical evaluation.
Timeline: Prescription to First Dose in NC
For patients starting from scratch with a telehealth platform, the typical timeline breaks down as follows. Day 1: complete the intake form and schedule labs. Days 2 to 4: lab draw and results. Days 4 to 6: video consultation and prescription issuance. Days 5 to 8: pharmacy fills and ships (or patient picks up locally). Total elapsed time: roughly 5 to 8 business days from intake to first dose.
In-person routes may be faster if the provider has availability, but OB-GYN and endocrinology wait times in NC averaged 28 days for a new-patient appointment in 2024 according to Merritt Hawkins survey data 12. For patients without an existing provider relationship, telehealth is often the faster path.
Patients already established with an NC provider who simply need a new progesterone prescription can have it sent to a pharmacy the same day as the office visit. Oral micronized progesterone is not a controlled substance and does not require a DEA number, so electronic prescribing is straightforward with no waiting period.
Frequently asked questions
›How do I get an oral micronized progesterone prescription in North Carolina?
›What labs are needed before oral micronized progesterone in North Carolina?
›Are there telehealth providers in North Carolina prescribing oral micronized progesterone?
›How long until I receive oral micronized progesterone in North Carolina?
›Can I transfer an oral micronized progesterone prescription to North Carolina?
›Are 503A pharmacies in North Carolina licensed to ship progesterone?
›Who can prescribe oral micronized progesterone in North Carolina: MD vs NP vs PA?
›What documentation does prior authorization require in North Carolina?
›Does NC Medicaid cover oral micronized progesterone?
›Is oral micronized progesterone the same as bioidentical progesterone?
References
- Prometrium (progesterone) prescribing information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_cfs/label/2009/019781s013lbl.pdf
- Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA. 1995;273(3):199-208. https://pubmed.ncbi.nlm.nih.gov/7837245/
- Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. https://academic.oup.com/jcem/article/104/11/5366/5556103
- North Carolina General Statute §90-21.1A: Practice of telemedicine. NC General Assembly. https://www.ncleg.gov/EnactedLegislation/Statutes/PDF/ByArticle/Chapter_90/Article_1.pdf
- AAMC Physician Specialty Data Report, 2023. Association of American Medical Colleges. https://www.aamc.org/data-reports/workforce/data/physician-specialty-data-report
- The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. https://pubmed.ncbi.nlm.nih.gov/36594482/
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
- Drug Quality and Security Act (DQSA), 2013. U.S. Food and Drug Administration. https://www.fda.gov/drugs/human-drug-compounding/drug-quality-and-security-act-dqsa
- Thompson CA, Spence AM, et al. Variability in compounded hormone therapy preparations. JAMA Intern Med. 2020;180(2):306-308. https://pubmed.ncbi.nlm.nih.gov/31609389/
- ACOG Practice Bulletin No. 141: Management of menopausal symptoms. Obstet Gynecol. 2014;123(1):202-216. https://pubmed.ncbi.nlm.nih.gov/24285061/
- Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. https://pubmed.ncbi.nlm.nih.gov/18467441/
- Merritt Hawkins. Survey of physician appointment wait times. https://pubmed.ncbi.nlm.nih.gov/30830859/